The GLP-1 receptor agonist, which are used in diabetes mellitus type two, has shown significant results in patients with NASH such as decreasing ALT levels, body weight, and hepatic fat. This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.